BREAKING NEWS: U.S. FDA Approves Lilly’s Ebglyss (Lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe AD
The U.S. Food and Drug Administration (FDA) has approved lebrikizumab-lbkz (Ebglyss, Lilly), a targeted interleukin (IL)-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies. Ebglyss 250 mg/2 […]